Business of Optometry News

The K8 implant, a first-in-class dual inflammasome inhibitor, demonstrated positive efficacy and safety at 3 months in five patients with bilateral geographic atrophy, according to a press release from Inflammasome Therapeutics.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

Bausch + Lomb launched the enVista Aspire monofocal and toric IOLs in the European Union, according to a press release.

Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments for age-related macular degeneration, according to a press release.

As physicians, we have all borne witness to patients dying at a young age, whether from an unforeseen illness or injury.

RhyGaze secured $86 million in a Series A financing round, which will be used to further the development of the company’s lead candidate gene therapy for optogenetic vision restoration, according to a press release.

City Therapeutics and Bausch + Lomb have entered into a strategic collaboration focused on the development of an RNA interference-based treatment for geographic atrophy, according to a press release.

Patients with presbyopia experienced improvements in near vision after treatment with Brimochol PF in a second phase 3 pivotal trial, according to a press release from Tenpoint Therapeutics.

Atsena Therapeutics initiated part B of the phase 1/2 LIGHTHOUSE study investigating ATSN-201 for the treatment of X-linked retinoschisis, according to a press release.